


<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office 	<b>Docket No.:</b> SCRIP1460	<b>Application No.:</b> 09/922,236
	<b>Applicants:</b> Hugli, et al.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> August 2, 2001	<b>Group Art Unit:</b> Not Yet Assigned 1644

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

PN	AA	Atkinson, J.P. 1986. Complement activation and complement receptors in systemic lupus erythematosus. <i>Semin. Immunol. Pathol.</i> 9:179-194
↓	AB	Budzko, D.B., V.A. Bokisch, and H.J. Muller-Eberhard. 1971. A fragment of the third component of human complement with anaphylatoxin activity. <i>Biochemistry.</i> 10:1166-1172.
↓	AC	Buyon, J.P., J. Tamerius, S. Ordorica, B. Young, and S.B. Abramson. 1992. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. <i>Athritis Rheum.</i> 35:55-61

<b>EXAMINER</b> Pat J. Noz	<b>DATE CONSIDERED</b> 6/13/05
-------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form 1449

Gray Cary\GT6264908.1  
740166-63

**BEST AVAILABLE COPY**

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SCRIP1460	<b>Application No.:</b> 09/922,236
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Applicants:</b> Hugli, et al.	
	<b>Filing Date:</b> August 2, 2001	<b>Group Art Unit:</b> <del>Not Yet Assigned</del> 1644

PN	AD	Chenoweth, D.E., S.W. Cooper, T.E. Hugli, R.W. Stewart, E.H. Blackstone, and J.W. Kirklin. 1981. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. <i>N. Engl. J. Med.</i> 304:497-503
	AE	Cooper, N.R. 1998. Complement and viruses. In <i>The Human Complement System in Health and Disease</i> . J.E. Volanakis and M.M. Frank, editors. Marcel Dekker, Inc., New York. 393-407
	AF	Craddock, P.R. J. Fehr, K.L. Brigham, R.S. Kronenberg, and H.S. Jacob. 1977. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. <i>N. Engl. J. Med.</i> 296:769-774
	AG	Drouet, C., L. Bouillet, F. Csoopaki, and M.G. Colomb. 1999. Hepatitis C virus NS3 serine protease interacts with the serpin C1 inhibitor. <i>FEBS Lett.</i> 458:415-418
	AH	Franco, A.G. and P.H. Schur. 1971. Hypocomplementemia in rheumatoid arthritis. <i>Arthritis Rheum.</i> 14:231-238
	AI	Hack, C.E., J.H. Nuijens, R.J. Felt-Bersma, W.O. Schreuder, A.J. Erenberg-Belmer, J. Paardekooper, W. Bronsveld, and L.G. Thijs. 1989. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with fatal outcome in sepsis. <i>Am. J. Med.</i> 86:20-26
	AJ	Hammerschmidt, D.E., P.R. Craddock, J. McCullough, R.S. Kronenberg, A.P. Dalmaso, and H.S. Jacob. 1978. Complement activation and pulmonary leukostasis during nylon fiber filtration leukapheresis. <i>Blood</i> 51:721:730
	AK	Harpel, P.C. and M.F. Lewin. 1985. Distribution of plasma kallikrein between C1 inactivator and $\alpha_2$ -macroglobulin in plasma utilizing a new assay for $\alpha_2$ -macroglobulin-kallikrein complexes. <i>J. Biol. Chem.</i> 260:4257-4263
✓	AL	Hayashi, J. and T.E. Hugli. 2000. Kallikrein-like activity associated with $\alpha_2$ -macroglobulin ( $\alpha_2$ -M) in plasma from liver transplant recipients. <i>Protein Science</i> 9:462-T.(Abstr.)


<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 6/13/05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SCRIP1460	<b>Application No.:</b> 09/922,236
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	<b>Applicants:</b> Hugli, et al.	
	<b>Filing Date:</b> August 2, 2001	<b>Group Art Unit:</b> Not Yet Assigned 1644

PN 13	AM	Hayashi, J., D.R. Salomon, and T.E. Hugli. Elevated kallikrein activity in plasma from stable liver transplant recipients. <i>Arterioscler. Thromb. Vasc. Biol.</i> , in press
14	AN	Heideman, M. and T.E. Hugli. 1984. Anaphylatoxin generation in multisystem organ failure. <i>J. Trauma</i> 24:1038-1043
15	AO	Hitomi, Y. and S. Fujii. 1982. Inhibition of various immunological reactions <i>in vivo</i> by a new synthetic complement inhibitor. <i>Int. Arch. Allergy Appl. Immunol.</i> 69:262-267
16	AP	Ikari, N., Y. Hitomi, and S. Fujii. 1983. New synthetic inhibitor to the alternative complement pathway. <i>Immunology.</i> 49:685-691.
17	AQ	Kaufman, N., J.D. Page, R.A. Pixley, R. Schein, A.H. Schmaier, and R.W. Colman. 1991. $\alpha_2$ -Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. <i>Blood.</i> 77:2660-2667
18	AR	Kirschfink, M., T. Wienert, K. Rother, and S. Pomer. 1992. Complement activation in renal allograft recipients. <i>Transplantation Proceedings.</i> 24:2556-2557
19	AS	Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. <i>Nature.</i> 227:680-685
20	AT	Love, R.A., H.E. Parge, J.A. Wickersham, Z. Hostomsky, N. Habuka, E.W. Moomaw, T. Adachi, and Z. Hostomska. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. <i>Cell.</i> 87:331-342
21	AU	Moon, K.E., J.P. Gorski, and T.E. Hugli. 1981. Complete primary structure of human C4a anaphylatoxin. <i>J. Biol. Chem.</i> 256:8685-8692.
22	AV	Motta, G., R. Rojkaer, A.A.K. Hasan, D.B. Cines, and A.H. Schmaier. 1998. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. <i>Blood.</i> 91:516-528
23	AW	Moxley, G. and S. Ruddy. 1987. Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. <i>Arthritis Rheum.</i> 30:1097-1104

EXAMINER 	DATE CONSIDERED 6/13/05
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SCRIP1460	<b>Application No.:</b> 09/922,236
	<b>Applicants:</b> Hugli, et al.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> August 2, 2001	<b>Group Art Unit:</b> <del>Not Yet Assigned</del> 1644


PN OIPE DEC 19 2001 PN	AX 24	Nusbacher, J., S.I. Rosenfeld, J.L. MacPherson, P.A. Thiem and J.P. Leddy. 1978. Nylon fiber leukapheresis: associated complement component changes and granulocytopenia. <i>Blood</i> . 51:359-365
PN	AY	Patrick, R.A., S.B. Taubman, and I.H. Lepow. 1970. Cleavage of the fourth component of human complement (C4) by activated C1s. <i>Immunochemistry</i> . 7:217-225
PN	AZ	Petry, F. and M. Loos. 1998. Bacteria and complement. <i>In the Human Complement System in Health and Disease</i> . J.E. Volanakis and M.M. Frank, editors. Marcel Dekker, Inc. New York. 375-391.
	BA	Pfeifer, P.H., J.J. Brems, M. Brunson, and T.E. Hugli. 2000. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. <i>Immunopharmacology</i> . 46:163-174
	BB	Pfeifer, P.H., M. Kawahara, and T.E. Hugli. 1999. Possible mechanism for <i>in vitro</i> complement (C) activation in blood and plasma samples: Futhan/EDTA controls <i>in vitro</i> complement activation. <i>Clin. Chem</i> . 45:1190-1199
	BC	Reid, K.B.M. 1998. Clq and mannose-binding lectin. <i>In the Human Complement System in Health and Disease</i> . J. Volanakis and M. Frank, editors. Marcel Dekker, Inc., New York. 33-48
	BD	Renaux, J.L., M. Thomas, T. Crost, N. Loughraieb, and G. Vantard. 1999. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. <i>Kidney Int</i> . 55:1097-1103
	BE	Ronholm, E., H. Tomasdottir, J. Runeborg, A. Bengtsson, J.P. Bengtson, O. Stenqvist, and S. Friman. 1994. Complement system activation during orthotopic liver transplantation in man. <i>Transplantation</i> 57:1594-1597.
	BF	Schapira, M., C.F. Scott, and R.W. Colman. 1982. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. <i>J. Clin. Invest</i> . 69:462-468.
✓	BG	Schenkein, H.A. 1991. The role of complement in periodontal diseases. <i>Crit. Rev. Oral Biol. Med</i> . 2:65-81


<b>EXAMINER</b> [Signature]	<b>DATE CONSIDERED</b> 6/13/05
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SCRIPI460	<b>Application No.:</b> 09/922,236
	<b>Applicants:</b> Hugli, et al.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> August 2, 2001	<b>Group Art Unit:</b> <del>Not Yet Assigned</del> 1644

	BH	Scholz, T.L., Blackman, O. Mathisen, L. Buo, T. Karlsrud, H.T. Johansen, A. Bergan, G.B. Klintmalm, and A.O. Aasen. 1995. Activation of the plasma ciontact system and hemodynamic changes after graft revascularization in liver transplantation. <i>Transplantation</i> 60:36-40
	BI	Teitel, J.M., K.A. Bauer, H.K. Lau, and R.D. Rosenberg. 1982. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F1/F1+2 fragment and thrombin-antithrombin complex. <i>Blood</i> 59:1086-1097.
	BJ	Veloso, D., L. Silver, S. Hahn, and R.W. Colman. 1987. A monoclonal anit-human plasma prekallilrein antibody that inhibits activation of prekillkrein by factor XIIa on a surface. <i>Blood</i> 70:1053-1062
	BK	Violi, F., D. Ferro, S. Basili, M. Artini, G. Valesini, M. Levvero, and C. Cordova. 1995. Increases rate of thrombin generation in hepatitis C virus cirrhotic patients. relationship to venous thrombosis. <i>J. Invest. Med.</i> 43:550-554.

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 6/13/05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

Gray Cary\GT6264908.1  
740166-63

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.:</b> SCRIP1460	<b>Application No.:</b> 09/922,236
	<b>Applicants:</b> Hugli, et al.	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Filing Date:</b> August 2, 2001	<b>Group Art Unit:</b> 3736 1644

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
PN	AA	4,016,042	04/05/1977	Lars G. Svendsen			
I	AB	4,428,874	01/31/1984	Lars G. Svendsen			
J	AC	4,753,875	06/28/1988	James W. Ryan			
✓	AD	5,780,265	07/14/1998	Dennis and Lazarus			

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
PN	AE	JP 59-203957 A	11/19/1984	JP			
PN	AF	JP 59-203958 A	11/19/1994	JP			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)


RECEIVED

JUL 9 2002

TECH CENTER 1600/2900

<b>EXAMINER</b> [Signature]	<b>DATE CONSIDERED</b> 6/13/05
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

Gray Cary\GT6296888.1  
740166-63